Big Tech Vets Back AI Drug Discovery
AI-driven drug discovery firm Converge Bio has raised $25M in a funding round backed by executives from Meta, OpenAI, and Wiz. The investment signals growing confidence from the mainstream tech industry in computational biology platforms designed to accelerate the development of new therapeutics.
The $25M Series A brings Converge Bio's total financing to $30 million, following a $5.5 million seed round in 2024. Founded in 2024, the company has grown to 34 employees and established partnerships with 40 pharmaceutical and biotech companies, running approximately 40 R&D programs on its platform. The company is headquartered in Boston and Tel Aviv. Converge Bio's platform is not a single model but an integrated system of proprietary AI tools designed to plug into existing drug development workflows. It trains generative AI models on molecular data—DNA, RNA, and protein sequences—to support various stages of the R&D lifecycle. This approach allows biologists to generate results without needing to write code or build their own infrastructure. The company offers three main AI systems for antibody design, protein yield optimization, and the discovery of biomarkers and drug targets. In over 40 completed programs, the platform has helped partners discover novel antibodies, improve protein manufacturing yields by 4 to 7 times, and identify molecular biomarkers. CEO Dov Gertz emphasizes that the models are trained on biological data, not text-based models, for a core scientific understanding. The leadership team combines expertise in machine learning, computational biology, and drug development. CEO Dov Gertz developed a machine-learning method for discovering CRISPR systems in collaboration with Nobel laureate Jennifer Doudna. CSO Iddo Weiner has led two drug programs to successful Phase 2 clinical readouts, and CTO Oded Kalev is a former cybersecurity AI lead who has advised U.S. government agencies on large-scale generative AI applications. The investment from tech executives signals a bet on engineering excellence—data, infrastructure, and trust—as a key differentiator in biotech AI, treating it as a scalable, software-first digital service. This follows a trend of increasing investment in AI for drug discovery, which saw $2.54 billion raised across 32 deals in 2025, a four-year high. The backing reflects growing confidence in platform companies that combine AI with proprietary biological data and wet-lab infrastructure. This convergence of AI and biotech directly impacts biomanufacturing by enabling the creation of "digital twins"—virtual models of bioprocesses that can simulate and optimize manufacturing parameters before physical trials. These models leverage real-time sensor data to predict and mitigate process deviations, reduce batch failures, and accelerate scale-up from lab to commercial production, a key step in implementing Pharma 4.0 standards. For cell and gene therapies, this can help overcome challenges in maintaining consistent product quality across different batches. A significant hurdle in this digital transformation is the integration of data from disparate sources into a cohesive infrastructure, a challenge addressed by modern Laboratory Information Management Systems (LIMS). Implementing a LIMS is a critical step for GMP environments to move away from paper-based records, enhance data traceability, and ensure regulatory compliance. The selection of a flexible LIMS is crucial for accommodating future scalability needs and avoiding vendor bias.
